Professional flash continuous glucose monitoring as a supplement to A1C in primary care

References

• Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. New Engl J Med. 1993;329:977–986.
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–853.
   PubMed Web of Science ®Google Scholar
• Bailey TS, Grunberger G, Bode BW, et al. American Association of Clinical Endocrinologists and American College of Endocrinology 2016 outpatient glucose monitoring consensus statement. Endocr Pract. 2016;22:231–261.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Glycemic targets. Sec 6. In standards of medical care in diabetes—2017. Diabetes Care. 2017;40:S48–S56.
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Promoting health and reducing disparities in populations. Sec 1. In standards of medical care in diabetes—2017. Diabetes Care. 2017;40:S6–S10.
   PubMedGoogle Scholar
• International Diabetes Federation. Guideline on Self-Monitoring of Blood Glucose in Non-Insulin Treated Type 2 Diabetes.2009 [cited 2017 Apr 4]. https://www.idf.org/e-library/guidelines/85-self-monitoring-of-blood-glucose-in-non-insulin-treated-type-2-diabetes.html
   Google Scholar
• Dailey G. Assessing glycemic control with self-monitoring of blood glucose and hemoglobin A1c measurements. Mayo Clin Proc. 2007;82:229–235, quiz 236.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Schikman CH, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structure Testing Program study. Diabetes Care. 2011;34:262–267.
   PubMed Web of Science ®Google Scholar
• Polonsky WH, Fisher L, Schikman CH, et al. A structured self-monitoring of blood glucose approach in in type 2 diabetes encourages more frequent, intensive, and effective physician interventions: results from the STeP study. Diabetes Technol Ther. 2011;13:797–802.
   PubMed Web of Science ®Google Scholar
• Bhide M, Grey JM, Moser EG, et al. A primary care perspective on the use of continuous glucose monitoring in clinical practice. Diabetes Technol Ther. 2013;15:533–537.
   PubMed Web of Science ®Google Scholar
• Ali MK, Bullard KM, Saaddine JB, et al. Achievement of goals in U.S. diabetes care, 1999-2010. N Engl J Med. 2013;368:1613–1624.
   PubMed Web of Science ®Google Scholar
• Blevins T. Value and utility of self-monitoring of blood glucose in non-insulin-treated patients with type 2 diabetes mellitus. Postgrad Med. 2013;125:191–204.
   PubMed Web of Science ®Google Scholar
• Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. Diabetes Educ. 2004;30:112–125.
   PubMed Web of Science ®Google Scholar
• Schnell O, Alawi H, Battelino T, et al. Self-monitoring of blood glucose in type 2 diabetes: recent studies. J Diabetes Sci Technol. 2013;7:478–488.
   PubMedGoogle Scholar
• Bergenstal RM, Ahmann AJ, Bailey T, et al. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the Ambulatory Glucose Profile (AGP). Diabetes Technol Ther. 2013;15:198–211.
   PubMed Web of Science ®Google Scholar
• Distiller LA, Cranston I, Mazze R. First clinical experience with retrospective flash glucose monitoring (FGM) analysis in South Africa: characterizing glycemic control with ambulatory glucose profile. J Diabetes Sci Technol. 2016;10:1294–1302.
   PubMedGoogle Scholar
• Mazze RS, Lucido D, Langer O, et al. Ambulatory glucose profile: representation of verified self-monitored blood glucose data. Diabetes Care. 1987;10:111–117.
   PubMed Web of Science ®Google Scholar
• Blumer I. The contemporary role of masked continuous glucose monitoring in a real-time world. J Diabetes Sci Technol. 2016;10:790–792.
   PubMedGoogle Scholar
• Monnier L, Lapinski H, Collete C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26:881–885.
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Brownlee M. Beyond hemoglobin A1c—need for additional markers of risk for diabetic microvascular complications. Jama. 2010;303:2291–2292.
   PubMed Web of Science ®Google Scholar
• Cryer PE. Severe hypoglycemia predicts mortality in diabetes. Diabetes Care. 2012;35:1814–1816.
   PubMed Web of Science ®Google Scholar
• Vigersky RA. Escaping the hemoglobin A1c-centric world in evaluating diabetes mellitus interventions. J Diabetes Sci Technol. 2015;9:1148–1151.
   PubMedGoogle Scholar
• Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. Jama. 2006;295:1681–1687.
   PubMed Web of Science ®Google Scholar
• Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab. 2008;93:1345–1350.
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C, Leiter L, et al. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2007;30:185–188.
   PubMed Web of Science ®Google Scholar
• Qu Y, Jacober SJ, Zhang Q, et al. Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. Diabetes Technol Ther. 2012;14:1008–1012.
   PubMed Web of Science ®Google Scholar
• Monnier L, Wojtusciszyn A, Colette C, et al. The contribution of glucose variability to asymptomatic hypoglycemia in persons with type 2 diabetes. Diabetes Technol Ther. 2011;13:813–818.
   PubMed Web of Science ®Google Scholar
• Fonseca VA, Grunberger G, Anhalt H, et al. Continuous glucose monitoring: a consensus conference of the American Association of Clinical Endocrinologists and American College of Endocrinology. Endocr Pract. 2016;22:1008–1021.
   PubMed Web of Science ®Google Scholar
• Rubinow KB, Hirsch IB. Reexamining metrics for glucose control. Jama. 2011;305:1132–1133.
   PubMed Web of Science ®Google Scholar
• Saudek CD, Derr RL, Kalyani RR. Assessing glycemia in diabetes using self-monitoring of blood glucose and hemoglobin A1c. Jama. 2006;295:1688–1697.
   PubMed Web of Science ®Google Scholar
• Hirsch IB, Amiel SA, Blumer IR, et al. Using multiple measures of glycemia to support individualized diabetes management: recommendations for clinicians, patients, and payers. Diabetes Technol Ther. 2012;14:973–983.
   PubMed Web of Science ®Google Scholar
• Nathan DM, Kuenen J, Borg R, et al. Translating the A1C assay into estimated average glucose values. Diabetes Care. 2008;31:1473–1478.
   PubMed Web of Science ®Google Scholar
• Malka R, Nathan DM, Higgins JM. Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring. Sci Transl Med. 2016;8:359ra130.
   PubMed Web of Science ®Google Scholar
• Wright LA, Hirsch IB. Metrics beyond hemoglobin A1C in diabetes management: time in range, hypoglycemia, and other parameters. Diabetes Technol Ther. 2017;19:S16–S26.
   PubMed Web of Science ®Google Scholar
• Herman WH, Dungan KM, Wolffenbuttel BH, et al. Racial and ethnic differences in mean plasma glucose, hemoglobin A1c, and 1,5-anhydroglucitol in over 2000 patients with type 2 diabetes. J Clin Endocrinol Metab. 2009;94:1689–1694.
   PubMed Web of Science ®Google Scholar
• Soranzo N, Sanna S, Wheeler E, et al. Common variants in 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways. Diabetes. 2010;59:3229–3239.
   PubMed Web of Science ®Google Scholar
• Wilson DM, Xing D, Cheng J, et al. Persistence of individual variations in glycated hemoglobin: analysis of data from the Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Randomized Trial. Diabetes Care. 2011;34:1315–1317.
   PubMed Web of Science ®Google Scholar
• Desouza CV, Rosenstock J, Zhou R, et al. Glycated albumin at 4 weeks correlates with A1C levels at 12 weeks and reflects short-term glucose fluctuations. Endocr Pract. 2015;21:1195–1203.
   PubMed Web of Science ®Google Scholar
• Cohen RM, Snieder H, Lindsell CJ, et al. Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins. Diabetes Care. 2006;29:1739–1743.
   PubMed Web of Science ®Google Scholar
• Au N, Mr H, Dr M, et al. Evidence for consistency of the glycation gap in diabetes. Diabetes Care. 2011;34:1712–1716.
   PubMed Web of Science ®Google Scholar
• Hanefeld M, Koehler C, Schaper F, et al. Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis. 1999;144:229–235.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57:1349–1354.
   PubMed Web of Science ®Google Scholar
• Testa MA, Gill J, Su M, et al. Comparative effectiveness of basal-bolus versus premix analog insulin on glycemic variability and patient-centered outcomes during insulin intensification in type 1 and type 2 diabetes: a randomized, controlled, crossover trial. J Clin Endocrinol Metab. 2012;97:3504–3514.
   PubMed Web of Science ®Google Scholar
• Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab. 2013;98:3411–3419.
   PubMed Web of Science ®Google Scholar
• Goto A, Arah OA, Goto M, et al. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. Bmj. 2013;347:f4533.
   PubMed Web of Science ®Google Scholar
• Kong AP, Yang X, Luk A, et al. Severe hypoglycemia identifies vulnerable patients with type 2 diabetes at risk for premature death and all-site cancer: the Hong Kong diabetes registry. Diabetes Care. 2014;37:1024–1031.
   PubMed Web of Science ®Google Scholar
• Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173:1300–1306.
   PubMed Web of Science ®Google Scholar
• Willis WD, Diago-Cabezudo JI, Madec-Hily A, et al. Medical resource use, disturbance of daily life and burden of hypoglycemia in insulin-treated patients with diabetes: results from a European online survery. Expert Rev Pharmacoecon Outcomes Res. 2013;13:123–130.
   PubMed Web of Science ®Google Scholar
• Cryer PE. Hypoglycaemia: the limiting factor in the glycaemic management of Type I and Type II diabetes. Diabetologia. 2002;45:937–948.
   PubMed Web of Science ®Google Scholar
• Cryer PE. Glycemic goals in diabetes: trade-off between glycemic control and iatrogenic hypoglycemia. Diabetes. 2014;63:2188–2195.
   PubMed Web of Science ®Google Scholar
• Bergenstal RM. Glycemic variability and diabetes complications: does it matter? Simply put, there are better glycemic markers! Diabetes Care. 2015;38:1615–1621.
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Public Workshop: Diabetes Outcome Measures Beyond Hemoglobin A1c (HbA1c); [updated 2016 Aug 31; cited 2017 Jul 3]. Available from: http://www.fda.gov/Drugs/NewsEvents/ucm499281.htm
   Google Scholar
• Lipska KJ, Ross JS, Wang Y, et al. National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999-2011. JAMA Intern Med. 2014;174:1116–1124.
   PubMed Web of Science ®Google Scholar
• Quilliam BJ, Simeone JC, Ozbay AB, et al. The incidence and costs of hypoglycemia in type 2 diabetes. Am J Manag Care. 2011;17:673–680.
   PubMed Web of Science ®Google Scholar
• Vigersky RA. The benefits, limitations, and cost-effectiveness of advanced technologies in the management of patients with diabetes mellitus. J Diabetes Sci Technol. 2015;9:320–330.
   PubMedGoogle Scholar
• Rodbard D. Continuous glucose monitoring: a review of successes, challenges, and opportunities. Diabetes Technol Ther. 2016;18:S3–S13.
   PubMed Web of Science ®Google Scholar
• Heinemann L, Freckmann G. CGM versus FGM; or, continuous glucose monitoring is not flash glucose monitoring. J Diabetes Sci Technol. 2015;9:947–950.
   PubMedGoogle Scholar
• Vigersky R, Shrivastav M. Role of continuous glucose monitoring for type 2 in diabetes management and research. J Diabetes Complicat. 2017;31:280–287.
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services. U.S. Food and Drug Administration: approval Order: freestyle Libre Pro Flash Glucose Monitoring System. PI50021. Sliver Spring (MD): Department of Health and Human Services; 2016.
   Google Scholar
• Bonora B, Maran A, Ciciliot S, et al. Head-to-head comparison between flash and continuous glucose monitoring systems in outpatients with type 1 diabetes. J Endocrinol Invest. 2016;39:1391–1399.
   PubMed Web of Science ®Google Scholar
• Bailey T, Bode BW, Christiansen MP, et al. The performance and usability of a factory-calibrated flash glucose monitoring system. Diabetes Technol Ther. 2015;17:787–794.
   PubMed Web of Science ®Google Scholar
• Bolinder J, Antuna R, Geelhoed-Duijvestijn P, et al. Novel glucose-sensing technology and hypoglycemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. Lancet. 2016;388:2254–2263.
   PubMed Web of Science ®Google Scholar
• Dunn T, Xu Y, Hayter G. Evidence of a strong association between frequency of flash glucose monitoring and glucose control measures during real-world usage. Diabetes Technol Ther. 2017;19:A-1-A-133, Abstract 034.
   Google Scholar
• Haak T, Hanaire H, Ajjan R, et al. Flash glucose-sensing technology as a replacement for blood glucose monitoring for the management of insulin-treated type 2 diabetes: a multicenter, open-label randomized controlled trial. Diabetes Ther. 2017;8:55–73.
   PubMed Web of Science ®Google Scholar
• Haak T, Hanaire H, Ajjan R, et al. Use of flash glucose-sensing technology for 12 months as a replacement for blood glucose monitoring in insulin-treated type 2 diabetes. Diabetes Ther. 2017;8:573–586.
   PubMed Web of Science ®Google Scholar
• Carlson AL, Mullen DM, Bergenstal RM. Clinical use of continuous glucose monitoring in adults with type 2 diabetes. Diabetes Technol Ther. 2017;19:S4–S11.
   PubMed Web of Science ®Google Scholar
• Rodbard D. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther. 2009;11:551–565.
   PubMed Web of Science ®Google Scholar
• Monnier L, Colette C, Wojtusciszyn A, et al. Toward defining the threshold between low and high glucose variability in diabetes. Diabetes Care. 2017;40:832–838.
   PubMed Web of Science ®Google Scholar
• Rodbard D. Clinical interpretation of indices of quality of glycemic control and glycemic variability. Postgrad Med. 2011;123:107–118.
   PubMed Web of Science ®Google Scholar
• Hammond P. Interpreting the ambulatory glucose profile. Br J Diabetes. 2016;16:S10–S15.
   Web of Science ®Google Scholar
• Matthaei S, Dealaiz RA, Bosi E, et al. Consensus recommendations for the use of Ambulatory Glucose Profile in clinical practice. Br J Diabetes Vasc Dis. 2014;14:153–157.
   Google Scholar
• Fonseca V, Grunberger G. Letter to the editor. Endocr Pract. 2017;23:629–632.
   PubMed Web of Science ®Google Scholar